Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 0.38.

  • Apellis Pharmaceuticals' Equity Ratio rose 4411.72% to 0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.38, marking a year-over-year increase of 4411.72%. This contributed to the annual value of 0.26 for FY2024, which is 470.17% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Equity Ratio stood at 0.38, which was up 4411.72% from 0.19 recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Equity Ratio ranged from a high of 0.42 in Q1 2023 and a low of 0.33 during Q2 2022
  • Its 5-year average for Equity Ratio is 0.2, with a median of 0.26 in 2024.
  • In the last 5 years, Apellis Pharmaceuticals' Equity Ratio crashed by 17916.18% in 2021 and then skyrocketed by 53263.05% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Equity Ratio (Quarter) stood at 0.23 in 2021, then dropped by 0.82% to 0.22 in 2022, then increased by 10.37% to 0.25 in 2023, then grew by 4.7% to 0.26 in 2024, then skyrocketed by 46.74% to 0.38 in 2025.
  • Its Equity Ratio stands at 0.38 for Q3 2025, versus 0.19 for Q2 2025 and 0.2 for Q1 2025.